CORD-19:038354e8830fe01feb621a12e8a8c467a15b6354 / 163350-163749 JSONTXT

Annnotations TAB JSON ListView MergeView

    CORD-19-Sentences

    {"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T1022","span":{"begin":0,"end":399},"obj":"Sentence"},{"id":"T9846","span":{"begin":0,"end":399},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Sequence variation and susceptibility of influenza virus clinical isolates to zanamivir and oseltamivir prior to their introduction into clinical practice (Jenny McKimm-Breschkin, CSIRO Health Sciences and Nutrition, Parkville, Australia) Zanamivir and oseltamivir, which specifically inhibit the neuraminidases (NA) of influenza A and B viruses, were introduced into clinical practice in 1999-2000."}

    CORD-19_Custom_license_subset

    {"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T90","span":{"begin":0,"end":399},"obj":"Sentence"}],"text":"Sequence variation and susceptibility of influenza virus clinical isolates to zanamivir and oseltamivir prior to their introduction into clinical practice (Jenny McKimm-Breschkin, CSIRO Health Sciences and Nutrition, Parkville, Australia) Zanamivir and oseltamivir, which specifically inhibit the neuraminidases (NA) of influenza A and B viruses, were introduced into clinical practice in 1999-2000."}

    CORD-19-PD-MONDO

    {"project":"CORD-19-PD-MONDO","denotations":[{"id":"T867","span":{"begin":41,"end":50},"obj":"Disease"},{"id":"T868","span":{"begin":320,"end":329},"obj":"Disease"}],"attributes":[{"id":"A867","pred":"mondo_id","subj":"T867","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A868","pred":"mondo_id","subj":"T868","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Sequence variation and susceptibility of influenza virus clinical isolates to zanamivir and oseltamivir prior to their introduction into clinical practice (Jenny McKimm-Breschkin, CSIRO Health Sciences and Nutrition, Parkville, Australia) Zanamivir and oseltamivir, which specifically inhibit the neuraminidases (NA) of influenza A and B viruses, were introduced into clinical practice in 1999-2000."}